AU2019324747A1 - Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry - Google Patents

Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry Download PDF

Info

Publication number
AU2019324747A1
AU2019324747A1 AU2019324747A AU2019324747A AU2019324747A1 AU 2019324747 A1 AU2019324747 A1 AU 2019324747A1 AU 2019324747 A AU2019324747 A AU 2019324747A AU 2019324747 A AU2019324747 A AU 2019324747A AU 2019324747 A1 AU2019324747 A1 AU 2019324747A1
Authority
AU
Australia
Prior art keywords
compound
formula
antibody
cat
conjugate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2019324747A
Other languages
English (en)
Inventor
Borhane Annabi
Richard BÉLIVEAU
Jean-Christophe Currie
Michel Demeule
Alain LAROCQUE
Alain ZGHEIB
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transfert Plus SC
Original Assignee
Transfert Plus SC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transfert Plus SC filed Critical Transfert Plus SC
Publication of AU2019324747A1 publication Critical patent/AU2019324747A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/286—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C07K7/083—Neurotensin
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00—Methods of screening libraries
    • C40B30/04—Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2019324747A 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry Pending AU2019324747A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862722726P 2018-08-24 2018-08-24
US62/722,726 2018-08-24
US201962804063P 2019-02-11 2019-02-11
US62/804,063 2019-02-11
PCT/CA2019/051170 WO2020037434A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Publications (1)

Publication Number Publication Date
AU2019324747A1 true AU2019324747A1 (en) 2021-04-01

Family

ID=69591094

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2019324747A Pending AU2019324747A1 (en) 2018-08-24 2019-08-26 Methods and compounds for targeting sortilin receptors and inhibiting vasculogenic mimicry

Country Status (8)

Country Link
US (1) US20220000971A1 (https=)
EP (1) EP3844190A4 (https=)
JP (1) JP7592320B2 (https=)
CN (1) CN113286820B (https=)
AU (1) AU2019324747A1 (https=)
CA (1) CA3110414A1 (https=)
IL (1) IL281043A (https=)
WO (1) WO2020037434A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107708733B (zh) 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
CA3006313C (en) 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
TWI809147B (zh) 2018-07-13 2023-07-21 美商阿列克特有限責任公司 抗分揀蛋白抗體及其使用方法
CN116731113A (zh) * 2022-03-01 2023-09-12 上海智肽生物科技有限公司 针对sort1的多肽化合物及其药物偶联物
CN119403786A (zh) 2022-06-23 2025-02-07 德罗普尼尔生物有限公司 选择性诱导细胞外靶标在溶酶体中降解的双功能分子
CN120641133A (zh) * 2022-11-14 2025-09-12 瑟瑞技术公司 用于刺激抗肿瘤免疫应答的药物缀合物化合物
WO2025054707A1 (en) * 2023-09-11 2025-03-20 Theratechnologies Inc. Peptide conjugates of camptothecin analogs and uses thereof
WO2025208212A1 (en) * 2024-04-02 2025-10-09 Theratechnologies Inc. Combination therapies comprising peptide-drug conjugates targeting sortilin
WO2025236098A1 (en) * 2024-05-16 2025-11-20 Theratechnologies Inc. Peptide conjugates of maytansinoids and uses thereof
WO2026021513A1 (zh) * 2024-07-25 2026-01-29 上海湃鸿生物科技有限公司 一种多肽药物偶联物及其制备方法和应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016270874B2 (en) * 2015-06-03 2018-12-06 Tairx, Inc. Novel use of aryl-quinolin derivatives as inhibitors of vasculogenic mimicry
CA3006313C (en) * 2015-11-24 2020-02-11 Transfert Plus, S.E.C. Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

Also Published As

Publication number Publication date
JP2021535209A (ja) 2021-12-16
CN113286820B (zh) 2025-04-08
JP7592320B2 (ja) 2024-12-02
WO2020037434A1 (en) 2020-02-27
CN113286820A (zh) 2021-08-20
EP3844190A4 (en) 2022-06-08
CA3110414A1 (en) 2020-02-27
IL281043A (en) 2021-04-29
EP3844190A1 (en) 2021-07-07
US20220000971A1 (en) 2022-01-06

Similar Documents

Publication Publication Date Title
JP7592320B2 (ja) ソルチリン受容体を標的化し血管擬態を阻害するための方法及び化合物
JP7095035B2 (ja) 受容体媒介化学療法による癌の治療のためのペプチド化合物およびペプチドコンジュゲート
TWI772288B (zh) 基於艾日布林之抗體-藥物結合物及使用方法
KR20240082348A (ko) 항체, 이의 항체-약물 접합체 및 이의 용도
EP2698376A1 (en) Cancer-targeting peptides and uses thereof in cancer therapy
CN114980932B (zh) Sortilin结合缀合化合物、其组合物及其用于治疗癌症的用途
CN115297890A (zh) 用于对患癌的对象处置癌的抗meflin抗体和含有该抗体的药物组合物
US20190248912A1 (en) Abcg2 monoclonal antibody and uses thereof
US20250312468A1 (en) Anti-protac antibodies and complexes
WO2008079976A2 (en) Dimeric high affinity egfr constructs and uses thereof
WO2025140358A1 (en) A pharmaceutical composition of anti-fgfr3 antibody drug conjugate and applications thereof
Zhou et al. h3B7A-LDM, a novel anti-mesothelin antibody-drug conjugate with the potential to induce antitumor immunity, shows potent efficacy against solid tumors
TW202546005A (zh) 抗體-奧瑞他汀藥物偶聯物以及其製造及使用方法
EP4642482A1 (en) Vhh anti-protac antibodies and complexes
CN121494985A (zh) 靶向Trop2/EpCAM的双特异性抗体、抗体偶联药物及其制备方法与应用
HK1259948B (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
HK1259948A1 (en) Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy
Byun et al. Proof of Concept for the Single-Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein